Article

Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report.

Adult HSCT, King Faisal Cancer Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Bone marrow transplantation (Impact Factor: 3.47). 01/2009; 43(1):1-12. DOI: 10.1038/bmt.2008.389
Source: PubMed

ABSTRACT Although several centers are now performing allogeneic hematopoietic SCT (HSCT) in the Eastern Mediterranean (EM) region, the availability is still limited. Special issues including compatible donor availability and potential for alternative donor programs are discussed. In comparison to Europe and North America, differences in patterns of diseases and pre-HSCT general status, particularly for patients with BM failure, are described. Other differences including high sero-positivity for CMV, hepatitis B and C infection, and specific observations about GVHD and its relation to genetically homogeneous communities are also discussed. We report that a total of 17 HSCT programs (performing five or more HSCTs annually) exist in 9 countries of the EM region. Only six programs are currently reporting to European Group for Blood and Marrow Transplantation or Center for International Blood and Marrow Transplantation Research. A total of 7617 HSCTs have been performed by these programs including 5701 allogeneic HSCTs. The area has low-HSCT team density (1.56 teams per 10 million inhabitants vs 14.43 in Europe) and very low-HSCT team distribution (0.27 teams per 10 000 sq km area vs <1-6 teams in Europe). Gross national income per capita had no clear association with low-HSCT activity. Much improvement in infrastructure and formation of an EM regional HSCT registry are needed.

Download full-text

Full-text

Available from: Tahir Shamsi, Jul 06, 2015
0 Followers
 · 
391 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Several centers are now performing allogeneic hematopoietic stem cell transplantation (HSCT) in the World Health Organization Eastern Mediterranean Region (EMRO) but the availability is still limited due to high cost and the need for multi-disciplinary team and an advanced laboratory support. Special issues including compatible donor availability, potential for alternate donor programs, differences in pattern of disease, pre-HSCT general status particularly for patients with BM failure, high sero-positivity for CMV, Hepatitis B and C infection and specific observations about GVHD with its relation to genetically homogeneous community are discussed. A total of 17 HSCT programs (performing five or more HSCTs annually) exist in nine countries of the EM region. Only six programs are currently reporting to EBMT or IBMTR. A total of 7617 HSCTs including 5701 allogeneic HSCTs have been performed. Due to low HSCT team density (1.5583 teams/10 million inhabitants versus 14.4333 in Europe) and very low HSCT team distribution (0.2729 teams/10,000 sq km area versus <1 to 6 teams in Europe) only 70.8% of total population has access to such a program in EM region. GNI/capita had no clear association with low HSCT activity; however improvement in infrastructure and establishment of EM regional HSCT registry need prioritization.
    Transfusion and Apheresis Science 04/2010; 42(2):169-75. DOI:10.1016/j.transci.2010.01.012 · 1.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The use of ambulatory blood pressure (BP) monitoring (ABPM) has provided a method of BP assessment that may compensate for some of the limitations of isolated measurements. The authors here aim to examine prospectively the effectiveness of the commonly used 24-hour mean as a potential screening test for the early identification of gestational hypertension and preeclampsia. The authors analyzed 503 BP series from 71 healthy pregnant women and 256 series from 42 women who developed gestational hypertension or preeclampsia. BP was sampled at half-hour intervals during the day and hourly during the night for about 48 hours once every four weeks after the first visit to the hospital. Sensitivity slightly increases from the first to the third trimester of gestation, with values ranging from 31.8% for diastolic BP (DBP) in the second trimester to 84.1% for systolic BP (SBP) in the third trimester. Specificity, however, is as low as 6.9% for DBP in the first trimester. The positive predictive value does not reach 55% for any variable in any trimester, too low for a proper individualized diagnosis of gestational hypertension or preeclampsia. The advantages of ABPM over conventional casual sampling do not provide a proper test when relying for diagnosis in the 24-hour mean
    Engineering in Medicine and Biology Society, 1997. Proceedings of the 19th Annual International Conference of the IEEE; 01/1997
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hematopoietic stem cell transplantation (HSCT) has evolved into an accepted therapy for many congenital or acquired disorders of the hematopoietic system. It has seen major changes in indications and use of transplant techniques. HSCT is a high cost procedure and requires investments; information on trends is essential for patient counselling and healthcare planning. HSCT rates have increased worldwide. Increase is constant and predictable; the reasons therefore are manifold. Introduction of reduced intensity conditioning regimens has opened access to patients at older age and with comorbidities. Higher numbers of unrelated volunteer donors and cord blood products give access to HSCT for patients without family donors. For some well defined indications, HSCT has become the most cost efficient therapy in countries with limited resources. Use of HSCT is under discussion for nonhematopoietic indications, as is the use of nonhematopoietic stem cells for organ repair. HSCT is likely to continue to increase for currently established indications. Indications and technologies will vary between countries with limited or nonrestricted resources. The most cost effective approach might not be the same everywhere. Novel indications will emerge but time will be needed to confirm their benefit. Close observation of global trends will become an essential tool for healthcare agencies in order to provide the necessary infrastructure in time.
    Current opinion in hematology 09/2009; 16(6):420-6. DOI:10.1097/MOH.0b013e328330990f · 4.05 Impact Factor